Gilead Lenacapavir PURPOSE 5 Data: Twice-Yearly Yeztugo Reaches 85.6% PrEP Persistence Versus 46.3% for Daily F/TDF
Gilead Lenacapavir PURPOSE 5 results show 85.6% of participants on twice-yearly lenacapavir stayed persistent on PrEP at Week 52, versus 46.3% on daily oral F/TDF, with zero HIV acquisitions in the lenacapavir arm.
